Unknown

Dataset Information

0

Host cell mTORC1 is required for HCV RNA replication.


ABSTRACT:

Objective

Chronically HCV-infected orthotopic liver transplantation (OLT) recipients appear to have improved outcomes when their immunosuppressive regimen includes a mammalian target of rapamycin (mTOR) inhibitor. The mechanism underlying this observation is unknown.

Design

We used virological assays to investigate mTOR signalling on the HCV replication cycle. Furthermore, we analysed HCV RNA levels of 42 HCV-positive transplanted patients treated with an mTOR inhibitor as part of their immunosuppressive regimen.

Results

The mTOR inhibitor rapamycin was found to be a potent inhibitor for HCV RNA replication in Huh-7.5 cells as well as primary human hepatocytes. Half-maximal inhibition was observed at 0.01?µg/mL, a concentration that is in the range of serum levels seen in transplant recipients and does not affect cell proliferation. Early replication cycle steps such as cell entry and RNA translation were not affected. Knockdown of raptor, an essential component of mTORC1, but not rictor, an essential component of mTORC2, inhibited viral RNA replication. In addition, overexpression of raptor led to higher viral RNA replication, demonstrating that mTORC1, but not mTORC2, is required for HCV RNA replication. In 42 HCV-infected liver-transplanted or kidney-transplanted patients who were switched to an mTOR inhibitor, we could verify that mTOR inhibition decreased HCV RNA levels in vivo.

Conclusions

Our data identify mTORC1 as a novel HCV replication factor. These findings suggest an underlying mechanism for the observed benefits of mTOR inhibition in HCV-positive OLT recipients and potentiate further investigation of mTOR-containing regimens in HCV-positive recipients of solid organ transplants.

SUBMITTER: Stohr S 

PROVIDER: S-EPMC5136730 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Objective</h4>Chronically HCV-infected orthotopic liver transplantation (OLT) recipients appear to have improved outcomes when their immunosuppressive regimen includes a mammalian target of rapamycin (mTOR) inhibitor. The mechanism underlying this observation is unknown.<h4>Design</h4>We used virological assays to investigate mTOR signalling on the HCV replication cycle. Furthermore, we analysed HCV RNA levels of 42 HCV-positive transplanted patients treated with an mTOR inhibitor as part of  ...[more]

Similar Datasets

| S-EPMC2861710 | biostudies-literature
| S-EPMC3554081 | biostudies-literature
| S-EPMC4351987 | biostudies-literature
| S-EPMC3147998 | biostudies-literature
| S-EPMC7793585 | biostudies-literature
| S-EPMC3394201 | biostudies-literature
| S-EPMC4374698 | biostudies-literature
| S-EPMC5621699 | biostudies-literature
| S-EPMC18116 | biostudies-literature
| S-EPMC2862546 | biostudies-literature